CORONAVIRUS: DIAGNOSIS AND THERAPY IN HUMANS

VolverGo back

Resultados 452 results. LastUpdate Updated on 05/02/2023 [11:29:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days



Page1/19 nextPage   results/page


THERAPEUTIC AGENT FOR COVID-19

Publication No.: WO2023008530A1 02/02/2023

Applicant:

FUJIFILM TOYAMA CHEMICAL CO LTD [JP]

Absstract of: WO2023008530A1

The present invention provides a therapeutic agent for COVID-19 administered to COVID-19 patients negative for IgG antibodies against SARS-CoV-2 and/or IgA antibodies against SARS-CoV-2, the therapeutic agent containing, as an active ingredient, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof.

traducir

METHOD OF TREATING A PERSON AFFLICTED WITH COVID-19 AND PHARMACEUTICAL FORMULATION INCLUDING DAPSONE

Publication No.: US2023031810A1 02/02/2023

Applicant:

PULMONEM INC [CA]

Absstract of: US2023031810A1

A method for treating patients with COVID-19 and/or other respiratory conditions includes administering eighty-five milligrams of dapsone twice daily for twenty-one days. A variety of dapsone formulations and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.

traducir

Topical Compositions For Treating Skin Ailments

Publication No.: US2023032283A1 02/02/2023

Applicant:

YAZIGI SAMER [US]

Absstract of: US2023032283A1

Topical cream or ointment medications formulated by blending admixtures of various concentrations of active ingredients with a plurality of inactive excipient ingredients for treating acne and a variety of other similar skin ailments including, folliculitis, rosacea, boil, skin-flaking, minor wounds, cuts, and adverse skin-issues related to use of covid-19 protective face-masks covered-area rashes, acne and non-lethal insect bites.

traducir

METHODS FOR DEVELOPING CD3+CD8+ CELLS AGAINST MULTIPLE VIRAL EPITOPES FOR TREATMENT OF VIRAL INFECTIONS INCLUDING VARIANTS EVOLVING TO ESCAPE PREVIOUS IMMUNITY

Publication No.: WO2023009770A1 02/02/2023

Applicant:

TEVOGEN BIO INC [US]

Absstract of: WO2023009770A1

Disclosed herein are methods of preparing peptide specific cytotoxic T cells (CTLs) against an emerged strain of a virus. The methods include providing an initial peptide composition specific to a prior strain of a virus, against which prior CTLs were sensitized, wherein the prior CTLs have reduced efficacy against an emerged strain of a virus relative to their efficacy against the prior strain of the virus; identifying an immunodominant peptide against a prior strain of a virus in an initial peptide composition; reducing the proportion of an immunodominant peptide in an initial peptide composition to yield an immunodominant-peptide- diluted peptide composition; and sensitizing mononuclear cells with an immunodominant- peptide-diluted peptide composition, thereby producing expansion of the peptide specific CTLs against an emerged strain of a virus. The virus can be SARS-COV2 (COVID-19) and the emerged strain can be Delta or Omicron BA.2.75.

traducir

RAPID TEST DEVICE FOR THE DETECTION OF SARS-COV-2 VIRUSES AND THE RELATIVE ANTIBODY PRODUCTION

Publication No.: WO2023007352A1 02/02/2023

Applicant:

UNIV DEGLI STUDI MAGNA GRAECIA DI CATANZARO [IT]
POLITECNICO DI TORINO [IT]
FOND BRUNO KESSLER [IT]

Absstract of: WO2023007352A1

Rapid test device for the detection of SARS-CoV-2 viruses and for the relative antibody production comprising a substrate of the lateral flow immunochromatographic assay divided into 5 regions: a first reception area to receive the biological sample ("Sample Deposition"); a second area where the first reaction takes place between an analyte and the molecule used for its specific identification ("Conjugation pad"); a third area where the signal amplification uses the addition of the gold nanoparticles ("Signal amplification"); a fourth test area ("Test line") and a fifth control area ("Control Line") in which a second and third immunoreaction takes place, providing a visual reading of the test result by means of a window and two results visible by a colored strip. The "sample deposition" area comprises a filter having porosity of about 200 nm - 1 µm.

traducir

AMINO ACID COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF POST-ACUTE SEQUELAE OF COVID-19

Publication No.: WO2023009444A1 02/02/2023

Applicant:

AXCELLA HEALTH INC [US]

Absstract of: WO2023009444A1

This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for treating post-acute sequelae of COVID-19 comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.

traducir

FLUORESCENCE-BASED BIOSENSOR FOR SARS-COV-2 DETECTION AND QUANTIFICATION

Publication No.: WO2023007298A1 02/02/2023

Applicant:

UNIV DE TRAS OS MONTES E ALTO DOURO [PT]
REQUIMTE - REDE DE QUIM E TECNOLOGIA [PT]
INST SUPERIOR ENGENHARIA DO PORTO [PT]

Absstract of: WO2023007298A1

The present disclosure relates to a method for detection of biomolecules comprising the steps of collecting a biological sample comprising an analyte at a concentration of at least 0.01 pM; exposing the collected sample to a temperature ranging from 70-100 °C; incubating the sample with Cdots previously incubated with the probe, therefore obtaining a solution; carefully homogenising the resulting solution; subjecting the solution to an excitation source for acquisition of fluorescence; determining the fluorescence shift between a negative control and the sample; wherein the Cdots are in a suspension state and the proportion of Cdots for analyte in the sample are in a ratio of at least 1:0.5; and wherein a shift of fluorescence from the negative control to the sample indicates the presence of the biomolecule. The present disclosure also relates to an apparatus for carrying out the process according to the present invention comprising a sensing unit (A), connected by an optical fiber (B) to a sample holder (C), and a LED (D) and a kit for detection of biomolecules, in particular for diagnosis of SARS-CoV-2.

traducir

ACE2 FUSION PROTEINS AND USES THEREOF

Publication No.: WO2023006935A2 02/02/2023

Applicant:

FORMYCON AG [DE]

Absstract of: WO2023006935A2

The present invention relates to fusion proteins of ACE2 with IgM or IgG2 Fc and the medical use of these fusion proteins, in particular in the prevention or treatment of infections with coronaviruses such as SARS-CoV-2.

traducir

A SURROGATE CELL-BASED CORONA VIRUS SPIKE PROTEIN BLOCKING ASSAY

Publication No.: WO2023006267A1 02/02/2023

Applicant:

FRIEDRICH ALEXANDER UNIV ERLANGEN NUERNBERG [DE]

EP_4124865_A1

Absstract of: WO2023006267A1

To monitor infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and successful vaccination against coronavirus disease 2019 (COVID-19), the kinetics of neutralizing or blocking anti-SARS-CoV-2 antibody titers need to be assessed. Here, we report the development of a quick and inexpensive surrogate SARS-CoV-2 blocking assay (SUBA) using immobilized recombinant human ACE-2 (hACE-2, ACE-2) and human cells expressing the native form of surface SARS-CoV-2 spike protein. Spike protein-expressing cells bound to hACE-2 in the absence or presence of blocking antibodies were quantified by measuring the optical density of cell-associated crystal violet in a spectrophotometer. The advantages are that SUBA is a fast and inexpensive assay which does not require biosafety level 2- or 3- approved laboratories. Most importantly, SUBA detects blocking antibodies against the native trimeric cell-bound SARS-CoV-2 spike protein and can quickly be adjusted to quickly pre- screen already approved therapeutic antibodies or sera from vaccinated individuals for their ACE-2 blocking activities against any emerging SARS-CoV-2 variants.

traducir

IN VITRO METHOD FOR THE PROGNOSIS OF PATIENTS SUFFERING FROM SEPSIS

Publication No.: WO2023006744A1 02/02/2023

Applicant:

FUNDACION INST DE ESTUDIOS CIENCIAS DE LA SALUD DE CASTILLA Y LEON IECSCYL IBSAL [ES]
UNIV DE SALAMANCA [ES]
FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIV DE GETAFE FIB HUG [ES]
CONSORCIO CENTRO DE INVESTIG BIOMEDICA EN RED [ES]

EP_4124864_A1

Absstract of: WO2023006744A1

The present invention refers to an in vitro method for the prognosis of patients suffering from sepsis, preferably COVID-19 patients. In a preferred embodiment, a bad prognosis means that the patient has an increased risk of developing Acute respiratory distress syndrome (ARDS).

traducir

ORAL CARE COMPRISING SOLIDAGO EXTRACT

Publication No.: WO2023006656A1 02/02/2023

Applicant:

GIVAUDAN SA [CH]

Absstract of: WO2023006656A1

An oral care composition comprising a virucidally-effective proportion and biofilm- inhibiting proportion of a solidago extract. The use of solidago brings about a 4 log reduction in viruses. It is particularly effective against coronaviruses, including the SARS-CoV-2 virus.

traducir

SKIN CARE COMPRISING SAPONIN-CONTAINING QUILLAJA EXTRACT

Publication No.: WO2023006662A1 02/02/2023

Applicant:

GIVAUDAN SA [CH]

Absstract of: WO2023006662A1

A hand care composition comprising a virucidally-effective proportion of a saponin- containing quillaja extract. The composition is particularly effective against coronaviruses, including the SARS-CoV-2 virus.

traducir

DETECTION OF GENETIC VARIANTS

Publication No.: WO2023009961A2 02/02/2023

Applicant:

BIO RAD LABORATORIES INC [US]

Absstract of: WO2023009961A2

The subject invention pertains to the detection and differentiation of genetic variations by nucleic acid amplification. The invention provides methods of detecting one or more genetic variations in a nucleic acid that are in close proximity simultaneously. The invention further provides primer and probe oligonucleotides and methods of using said primers and probes in assays to detect genetic variants of concern of SARS-CoV-2. The methods of the invention detect genetic variants of other pathogens, including influenza, or genetic variants involved in inheritable diseases or cancer.

traducir

OPTIMIZED MULTIDIMENSIONAL BIOLOGICAL ACTIVITY OF POLY-ICLC WITH CONTROLLED COMPONENT SIZE AND FORMULATION

Publication No.: WO2023009171A2 02/02/2023

Applicant:

ONCOVIR INC [US]

Absstract of: WO2023009171A2

Poly-ICLC molecules and methods for producing them, including certain specific molecular weight molecules having improved activity in certain applications. These molecules may be incorporated in pharmaceutically or veterinary acceptable excipients and carriers for a number of uses in humans, in domestic animals and in wild animals. Such uses include (but are not limited to) prophylaxis pre-exposure prophylaxis, treatment and/or inflammatory symptom attenuation of viral or microbial infections; immunomodulating, vaccine adjuvant, antiviral, and/or anti-inflammatory effects mediated through activation of the MDA5, TLR3 and other dsRNA dependent enzyme systems; antineoplastic effects either alone or when combined with therapeutic vaccine or other anticancer immunologic agents; preventive cancer vaccine adjuvant effects in patients at risk for cancer. The molecules may be of particular use against SARS-CoV-2 infection or a cytokine storm caused by a SARS-CoV-2 infection. While dosage may be adjusted depending on the specific target and the specific patient, the dose should be sufficient to activate the MDA5 and TLR3 enzyme systems in the patient. For humans the dose is between approximately 0.5 and 50 micrograms per kilogram body weight. The nature of the molecule does not demand any specific route of administration. Therefore, the route can be selected based on the specific target and the specific patient, and could include (but not be limited to) IM, SC, IT, IV or IN. Preferabl

traducir

ANTI-VIRAL, ANTI-BACTERIAL HERBAL MEDICINE TO PREVENT THE TRANSMISSION AND SPREAD OF DISEASES TRANSMITTED BY RESPIRATORY TRACT AND SURFACE CONTACT

Publication No.: WO2023009080A1 02/02/2023

Applicant:

KURTULMUS MEHMET SERHAN [TR]

Absstract of: WO2023009080A1

The invention is related to an active substance used in the form of nasal and mouth spray, inhaler, cream, gel, lozenge, mouthwash, toothpaste, hand disinfectant, and surface disinfectant, in order to prevent the transmission and spread of viruses and bacteria that are transmitted by the respiratory tract and surface contact and that may threaten human and animal health, especially Sars Cov-2 virus and its variants. In particular, the invention is related to the active substance called Triacetin, which forms a layer on the mucosal surfaces such as the nasal and mouth mucosa without disturbing the user, thus preventing the entry of viruses and bacteria into the body by contacting these surfaces, which further with its solvent effect, a natural feature of the active substance, ensures the rapid deterioration of protein and lipid structures of the viruses and bacteria that come into contact with itself.

traducir

QUANTUM DOT CONJUGATED VIRUS SPIKE PROTEIN FOR CELL-BASED BIO-SENSING SYSTEMS AND DRUG SCREENING

Publication No.: WO2023009135A1 02/02/2023

Applicant:

THE GOVERNMENT OF THE US SECRETARY OF THE NAVY [US]

Absstract of: WO2023009135A1

Quantum dots conjugated to SARS-CoV-2 Spike protein receptor binding domain (RED) interact with gold nanoparticles bound to angiotensin converting enzyme 2 (ACE2) and thus undergo energy transfer. This energy transfer indicates RED /ACE binding and can be used to assay for inhibitors thereof. Moreover, these labeled quantum dots were found to undergo endocytosis in cells expressing ACE2.

traducir

NEUTRALIZING HUMAN ANTIBODY AGAINST WILD TYPE STRAIN AND MUTANT STRAIN OF SARS-COV-2 AND ANTIGEN-BINDING FRAGMENT THEREOF

Publication No.: WO2023008463A1 02/02/2023

Applicant:

EVEC INC [JP]
NAT CENTER FOR GLOBAL HEALTH AND MEDICINE [JP]

Absstract of: WO2023008463A1

The present invention provides a human-derived monoclonal antibody against SARS-CoV-2 coronavirus, said antibody binding to the S protein of SARS-CoV-2 coronavirus and neutralizing the viral activity, an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, and a pharmaceutical composition for treating or preventing SARS-CoV-2 coronavirus infection, said composition containing the antibody or the antigen-binding fragment thereof.

traducir

NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-COV-2 SPIKE PROTEINS, AND MRNA VACCINE SPIKE PROTEINS

Publication No.: WO2023010088A1 02/02/2023

Applicant:

PONO LIFESTYLE COLORADO LLC [US]

Absstract of: WO2023010088A1

Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and/or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-CoV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.

traducir

COVID-19 IMMUNE RESPONSE ASSAY METHOD

Publication No.: WO2023009984A1 02/02/2023

Applicant:

ORASURE TECH INC [US]

Absstract of: WO2023009984A1

Disclosed herein are assay methods and kits for for assessing the strength of the immune response to SARS-CoV-2 virus in a subject by allowing for rapid and efficient detection of neutralizing antibodies (NAbs) from serum of vaccinated and non-vaccinated subjects. The assay method can be conducted in a biosafety level 2 setting, and uses highly-purified, monomeric SARS-Cov-2-Spikel which leads to improved sensitivity and specificity over current state of the art assays.

traducir

THERAPEUTIC FORMULATIONS FROM PELARGONIUM SP. AND METHOD OF USE IN RESPIRATORY VIRAL INFECTIONS

Publication No.: WO2023009976A1 02/02/2023

Applicant:

SUBHADRA BOBBAN [US]

Absstract of: WO2023009976A1

The SARS-CoV-2 pandemic infected 504 million people with over 6.2 million deaths worldwide. Recent variants of SARS-CoV-2 are evolving faster and are more transmissible compared to the strain first reported. Broad-spectrum viral inhibitors that block the initial stages of infection by reducing virus binding and proliferation, thereby reducing disease severity is an unmet global medical need. A standardized polyphenolic-rich compound isolated from Pelargonium sidoides, against recombinant Vesicular Stomatitis Virus (rVSV)-pseudotyped SARS-CoV-2S (spike) of six different variants of SARS-CoV-2. Bi121 was effective in neutralizing all six rVSV-ΔG-SARS-CoV-2S variants expressing different mutations. The antiviral activity was then assessed against different variants of SARS-CoV-2 (USA WA1/2020, Hongkong/VM20001061/2020, B.1.167.2 (Delta)) and BA.1.1 (Omicron) in two different cell lines (Vero cells and HEK-ACE2) using RT-qPCR and plaque assays. Bi121 showed significant antiviral activity towards all the four SARS-CoV-2 variants tested, suggesting a broad-spectrum activity.

traducir

THERAPEUTIC SWABS FOR TREATING UPPER RESPIRATORY INFECTIONS

Publication No.: WO2023009150A1 02/02/2023

Applicant:

DHAWAN SUBHASH [US]

US_2023036304_PA

Absstract of: WO2023009150A1

The present invention offers Therapeutic Swabs device system as the first therapeutic approach intended to deliver plurality of antiviral, antimicrobial, cytoproteclive, anti-inflammatory, and low- or non-anticoagulant drugs to the nasal and oral cavities, nasopharynx, and posterior pharynx, the primary sites of upper respiratory infections. This invention enables an ideal multiprong therapeutic approach for effective targeting of serious upper respiratory infections in the humans and in animals. By virtue of the unique configuration of the Therapeutic Swabs device system comprising multiple drugs with distinctive functions, this system is highly desirable to maximize protection against deadly respiratory infections, including SARS-CoV-2, yet alleviating the undesired adverse side effects associated with systemic absorption of drugs administered via other routes. Since the upper respiratory disease-causing pathogens spread primarily through breathing, droplets of saliva, discharge from nasal secretions, or via other direct contacts, this invention offers a useful broadly applicable therapeutic approach to effectively control the current out-of-control COVID-19 pandemic and future viral outbreaks, and can be utilized by healthcare professionals, other individuals, friends and family members, or even by self-administration on a mass-scale.

traducir

Protease Inhibitors for Treatment of Coronavirus Infections

Publication No.: US2023033285A1 02/02/2023

Applicant:

THE SCRIPPS RES INSTITUTE [US]

Absstract of: US2023033285A1

Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions:wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.

traducir

Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases

Publication No.: US2023030607A1 02/02/2023

Applicant:

HERNANDEZ JOSE OCTAVIO [CL]

Absstract of: US2023030607A1

A novel oxygen pulse therapy methods of treating subjects suffering from COVID19 and other respiratory and others diseases are provided. Aspects of the methods including administering to the subjects an effective amount of oxygen as pulses through the respiratory tract are included. Also provided are methods of assessing severity of the disease, mild, moderate, severe, or critical, and oxygen doses and frequencies. The method can be applied to viral, bacterial, fungal or parasitic respiratory and others diseases infections such as corona virus (SARS-CoV-2), influenza virus such as influenza A or rotavirus, bacterial pneumonia and meningitis such as Streptococcus pneumonia or parasitic and other diseases such AIDS, Ebola, tuberculosis and malaria.

traducir

THERAPEUTIC SWABS FOR TREATING UPPER RESPIRATORY INFECTIONS

Publication No.: US2023036304A1 02/02/2023

Applicant:

DHAWAN SUBHASH [US]

Absstract of: US2023036304A1

Compounds and methods for preventing or treating upper respiratory virus infections in humans and animal species are disclosed. The compounds may exhibit antimicrobial, antiviral, anti-inflammatory, anticoagulant or cytoprotective activities. The methods may deliver compounds to be delivered to the nasal and oral cavities, nasopharynx, and posterior pharynx, the primary sites of upper respiratory infections, such as influenza, SARS, and SARS-CoV-2. Therapeutic swabs comprising one or more compounds are may be used to deliver one or more compounds to deliver the above primary sites of the individuals infected with one or more upper respiratory viruses or other pathogens.

traducir

METHOD AND KIT FOR DETECTION OF POLYNUCLEOTIDE

Nº publicación: US2023031670A1 02/02/2023

Applicant:

COUNCI OF SCIENT & INDUSTRIAL RESEARCH [IN]

AU_2020394910_A1

Absstract of: US2023031670A1

The invention describes a kit for detection of a target polynucleotide using a CRISPR effector system that comprises CAS9 from Francisella novicida, a synthetic sgRNA and a detection scheme based on binding and subsequent enzymatic cleavage of the target polynucleotide. The invention also describes a method for detection of a target polynucleotide using the kit. The kit can be el applied to both pathogenic and non-pathogenic polynucleotides and can be used to distinguish polynucleotides different by a single mismatch without the need for sequencing. The kit can also be used for detection of COVID-19. The kit is economical, easy to assemble and provides a robust and rapid readout that can be appropriately adapted for point of care applications.

traducir

Page1/19 nextPage results/page

punteroimgGo back